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Abstract
Background: The purpose of the study was to investigate the expression and prognostic value of STAT3 in diffuse
large B-cell lymphoma (DLBCL).
Methods: Seventy-four DLBCL patients from 2001 to 2007 were reviewed in the study. The STAT3 expression in
their tumor tissues was examined using the immunohistochemistry (IHC) method, and evaluated for its association
with clinicopathological parameters.
Results: Strong nuclear staining of STAT3 and phosphorylated-STAT3
tyr705 (P-STAT3) were observed in 19 cases
(25.7%) and 24 cases (32.4%), respectively, and the expression levels were highly consistent between them (P =
0.001). The high nuclear expression of STAT3 was more frequent in the non-germinal center B cell-like (non-GCB)
DLBCL than that in the GCB subtype, but not reaching significance (P < 0.061). The high nuclear expression of
STAT3 was found to be correlated with poor overall survival (OS) (P = 0.005). Multivariate Cox regression analysis
showed that the STAT3 expression was an independent prognostic factor for DLBCL patients regardless of CHOP or
R-CHOP regimen used as the first-line therapy.
Conclusion: STAT3 is more frequently expressed in non-GCB DLBCL than that in GCB subtype, and its strong
nuclear expression is correlated with poor OS in DLBCL.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is defined by
the World Health Organization (WHO) Classification as
a heterogeneous entity, encompassing morphologic and
genetic variants, and variable clinical presentations and
outcomes [1]. It accounts for 80% of aggressive lympho-
mas [2]. International Prognostic Index (IPI) is currently
used to predict the prognosis in DLBC [3], but its role
is limited[4]. Molecular subtypes of germinal center B
cell-like (GCB) and non-germinal center B cell-like
(non-GCB) DLBCL subtypes are proposed to stratify the
prognosis of DLBCL in addition to the IPI score [5-7],
but the application of Rituximab reduced the prognostic
difference between the two subtypes [8,9]. More prog-
nostic markers should be identified for DLBCL.
The Signal Transducers and Activators of Transcrip-
tion (STAT) family members play important roles in
transcriptional regulation and signal transduction, in
which STAT3 plays a critical role in regulation of cell
proliferation and survival [10] and is a critical transcrip-
tion activator in angiogenesis [11]. Hypermethylation
silencing of SOCS (the Suppressor of Cytokine Signal-
ing) genes leads to reactivation of STAT pathway,
resulting in the resistance to ABT-869, a promising
multi-targeted tyrosine kinase inhibitor [12]. STAT
pathway also triggers the activity of receptor-associated
Janus kinase (JAK) family members and cross-talks with
the nuclear factor-B( N F - B) pathway, which is an
important molecular pathogenesis of lymphoma [13].
Thus the STAT family has been actively studied as one
of molecular targets for anti-neoplastic therapy [14].
Expression of STAT3 in DLBCL subtypes may be vari-
able according to in vitro studies [15,16]. The cell line
studies showed that the activated B cell-like (ABC)
DLBCL had the highest level of STAT3 mRNA, roughly
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ever, the STAT3 expression and its prognostic value in
different subtypes of DLBCL tumors were not investi-
gated. In the study, we investigated the expression level
and frequency of STAT3 in DLBCL tumors, the differ-
ence of STAT3 expression in different DLBCL subtypes,
and its prognostic value in DLBCL patients.
Materials and methods
Patients
Seventy-four consented patients with DLBCL in the
Beijing Cancer hospital from 2001-2007 were studied. In
58 patients, 27 cases were treated with R-CHOP and 31
cases with CHOP as first-line regimens. The clinical
research protocol was approved by our Institutional
Review Board (IRB). Archived formalin-fixed and paraf-
fin-embedded tumor tissues were obtained from our
Department of Pathology.
Immunohistochemical analysis (IHC)
4 μm thick sections were mounted on APES-coated
slides. After dewaxing in xylene and rehydrating in a
gradient concentration of ethanol, the slides were
immersed in methanol containing 0.3% hydrogen perox-
ide for 15 minutes to block endogenous peroxidase
activity. All slides were pretreated with an antigen
retrieval method by heating the slides in an autoclave in
citrate buffer (10 mM, pH 6.0) for 90 seconds except
those stained for P-STAT3. EDTA-Tris buffer (1 mM,
pH 9.0) was used for pretreating before P-STAT3 stain-
ing. After rinsing in TBS (pH7.6), the specimens were
incubated for 2 h at 37°C with anti-STAT3 antibody
(sc-7179 rabbit polyclonal antibody, Santa Cruz Biotech-
nology) for STAT3, anti-P-STAT3 antibody (9145, rab-
bit monoclonal antibody, Cell Signaling Technology) for
P-STAT3
Tyr705, and antibodies for BCL6, CD10, MUM-
1 (Santa Cruz Biotechnology). Subsequently, all slides
were incubated with Envision HRP antibody working
fluid (Dako Company) for 30 minutes at 37°C, and then
developed with DAB-H2O2 solution (Dako Company).
The cell nuclei were stained with Meyer’s hemotoxylin.
The normal tonsil tissue was used as a negative control
and breast cancer tissue stained positive was used as a
positive control for STAT3 and P-STAT3 in all experi-
ments. For technical details, see the manufacturer’s
instructions for each reagent.
IHC staining was evaluated by two independent
experienced pathologists, who were blinded to the clini-
cal data. As for the nuclear staining, at least 100 tumor
cells per specimen were counted and only specimens
showing moderate to strong immunoreactivity were
considered positive. Staining was considered strong
positive when > 75% of tumor cell nuclei were stained
positive for STAT3 and > 30% of tumor cell nuclei for
P-STAT3. Specimens stained positive for STAT3 ≤ 75%
and ≤ 30% for P-STAT3 were considered weak
immunoreactivity.
Statistics
The Chi-square test was used to analyze the consistence
of expressions of STAT3 in nucleus and P-STAT3. Cor-
relation analysis of the STAT3 expression and the P-
STAT3 level with clinicopathological variables was per-
formed by two-sided Chi-square test. Kaplan-Meier
method was used to estimate difference of OS. OS was
defined as the time from diagnosis to death or the last
follow-up. The Cox regression model was used to evalu-
ate the prognostic value. The statistical software
SPSS16.0 was used for all the statistical analysis.
Results
Patient characteristics
All patients had complete follow-up information from
the Tumor Registry Office in our hospital. The clinico-
pathological characteristics are summarized in Table 1.
Fifty five patients were younger than 60 years old. Male
and female patients were 30 and 44, separately. Twenty
nine patients were diagnosed with B symptoms, 50
patients had stage III-IV diseases and 50 patients were
diagnosed with the non-GCB subtype.
STAT3 expression
Among the 74 patients, 66 cases (89.19%) had the
STAT3 expression, including 19 cases (25.7%) with
strong nuclear staining of STAT3, and 24 cases (32.4%)
with strong nuclear staining of P-STAT3. Representative
staining outcomes were shown in Figure 1. There
existed a consistence between the STAT3 expression
and the P-STAT3 level (P = 0.001), indicating the relia-
bility and accuracy of our IHC analysis (Table 2).
Correlation between the nuclear expression of STAT3 and
clinicopathological parameters
We observed the associations of the STAT3 nuclear
expression with IPI score and molecular subtypes, but
no statistical significances were reached (P =0 . 0 9 9a n d
P = 0.061, respectively). No association was found
between the STAT3 nuclear expression and other fac-
tors, including B symptoms, age of onset, clinical stage,
and erythrocyte sedimentation rate (ESR), lactate dehy-
drogenase (LDH), and tumor size (Table 1).
Association between the nuclear expression of STAT3 and
overall survival
Kaplan-Meier analysis showed that strong STAT3
nuclear expression was correlated with poorer OS (P =
0.005) (Figure 2). Other factors such as serum LDH
level, clinical stage, B symptoms, tumor size, and IPI
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n o ts h o w n )a sr e p o r t e di no t h e rs t u d i e s ,w h i c hc o n -
firmed our data is reliable. A forward stepwise multivari-
ate Cox model analysis, incorporating the above factors,
demonstrated that the nuclear expression of STAT3 (P
= 0.001), LDH level (P = 0.002) and tumor size (P =
0.025) were independent prognostic factor for OS.
To analyze the prognostic implication of STAT3 in
term of Rituximab therapy, we stratified all patients into
two subgroups, the CHOP subgroup and the R-CHOP
subgroup. In CHOP subgroup, high nuclear expression
of STAT3 predicted poor survival (P =0 . 0 0 1 ) .I nR -
CHOP subgroup, 2 of 19 cases died of DLBCL in low
STAT3 cohort and 3 of 8 cases died in high STAT3
cohort. No significant association was observed between
the expression of STAT3 and prognosis (P =0 . 2 1 6 )i n
the R-CHOP subgroup. But the survival curve showed
that high STAT3 expression indicated poor OS in the
first 40 months. Thus, it needs to increase the sample
size to confirm this result (Table 3, Figure 3).
Discussion
Lam LT[15] et al. reported that activated B-cell diffuse
large B-cell lymphoma (ABC-DLBCL) had higher level
of STAT3 mRNA than that in GCB-DLBCL. Detection
with immunohistochemistry [15] showed that slightly
more cases with high nuclear expression of STAT3 were
observed in the non-GCB DLBCL group and the high
expression rates were 12.5% and 32.4% in GCB and
non-GCB subtypes, respectively. However, no statistical
s i g n i f i c a n c ew a sf o u n d .T h i si sm o s tl i k e l yd u et ot h e
small sample size. Our study showed that the frequency
of high nuclear expression of STAT3 in DLBCL was
25.7% with 12.5% in GCB subgroup and 32% in non-
GCB subgroup, but not reaching significance (P =
0.061).
L a mL Te ta l .[ 1 5 ]a l s od e m o n s t r a t e dt h a th i g h
S T A T 3e x p r e s s i o ni nA B C - D LBCL patients correlated
with inferior overall survival, but not with GCB-DLBCL
patients. However, STAT3-high and STAT3-low subsets
within ABC-DLBCL did not differ in prediction of over-
all survival. Our study showed that high nuclear expres-
sion of STAT3 in DLBCL possibly correlated with poor
overall survival, especially in patients receiving CHOP
regimen. This poor outcome may be explained at least
in part by the multiple cellular functions of STAT3,
which is a critical component of diverse signal transduc-
tion pathways[15,17,18]. STAT3 regulates the expression
of a number of genes (e.g. survivin, bcl-xl, mcl-1) that
modulate cell survival, differentiation, and proliferation
(e.g. c-myc, cyclin D1, p21, cyclin E), invasion and
metastasis (e.g. matrix metalloproteinase-9 and 2)[19],
and angiogenesis (e.g. vascular endothelial growth fac-
tor) [11,20,21]. STAT3 can restrain anti-tumour
immune responses [22-27] and regulate key cancer-pro-
moting inflammatory mediators, which can initiate or
promote oncogenic transformation, and genetic and epi-
genetic changes in malignant cells [28,29].
Our study also demonstrated the possibility of using
immunohistochemistry to detect STAT3 expression in
routine pathologic specimens, which may enable us con-
veniently to identify DLBCL cases with poor clinical
Table 1 Clinicopathological parameters and their correlations with STAT3 nuclear expression
Clinical Parameters No.# Nuclear Staining P Value Clinical Parameters No.# Nuclear Staining P Value
Low positive Strong positive Low positive Strong positive
Gender Stage
Male 30 20 10 0.165 I~II 24 18 6 0.582
Female 44 35 9 III~IV 50 37 13
Age IPI
< 60 55 43 12 0.161 0~2 48 39 9 0.099
≥ 60 19 12 7 3~4 22 14 8
B symptoms Bulky mass
positive 29 23 6 0.306 ≥ 10 cm 9 6 3 0.440
negative 45 32 13 < 10 cm 55 47 16
LDH Molecular subtypes
positive 28 19 9 0.235 GCB 24 21 3 0.061
negative 46 36 10 non-GCB 50 34 16
b2-MG Treatment regimens
positive 46 34 12 0.513 CHOP 31 22 9
negative 17 12 5 R-CHOP 27 19 8
ESR
positive 38 28 10 0.406
negative 29 23 6
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Figure 1 STAT3 expression and P-STAT3 level in DLBCL (A)
negative nuclear staining of STAT3, (B) negative nuclear
staining of P-STAT3, (C) weak nuclear staining of STAT3, (D)
weak nuclear staining of P-STAT3, (E) strong nuclear staining
of STAT3, (F) strong nuclear staining of P-STAT3.












Low positive 43 7 50
Strong
positive
12 12 24 0.001
Total 55 19 74





Figure 3 Kaplan-Meier curve of overall survival (OS) in patients
with different treatment regimens using STAT3 nuclear
expression. (A) Patients received the CHOP regimen; (B) Patients
received the R-CHOP regimen.
Table 3 Correlation of STAT3 nuclear expression with
overall survival
treatment STAT3 OS P
positive negative
CHOP Low 1 21 0.001
High 3 6
R-CHOP Low 2 17 0.216
High 3 5
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intensive treatment for those patients.
Since STAT3 plays a critical role in tumor initiation
and progression, inhibition of STAT3 activation would
be an effective approach for cancer prevention and
treatment. Our findings may provide a basis for the
application of STAT3 inhibitors in the future.
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